Special Updates

Melanoma and Skin Cancer Awareness Month

May is melanoma and skin cancer awareness month. Skin cancer is very common with over 5 million patients diagnosed each year in the United States. NeoGenomics offers a wide range of testing for your patients including next-generation sequencing (NGS) panels such as Neo Comprehensive^™ - Solid Tumor and NeoTYPE^® Melanoma Profile, smaller panels like RAS/RAF Panel to single gene assays such as BRAF IHC and BRAF PCR. Personalized patient care starts with precision oncology and NeoGenomics is your trusted partner for oncology testing.

FOLR1 Ovarian Cancer Testing Program

NeoGenomics Laboratories and our partnership with ImmunoGen, Inc. continues to offer the FOLR1 testing program which provides testing for folate receptor alpha (FRα), an actionable biomarker in ovarian cancer, to eligible patients.

Approximately 35% of ovarian cancer patients are expected to be positive for folate receptor alpha (FRα)1, meaning over a third of people with advanced ovarian cancer may have a different treatment option.

Testing for FRα expression is performed using the FDA-approved immunohistochemistry (IHC) companion diagnostic (CDx)—VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. This CDx may indicate eligibility for treatment with the associated biomarker-driven therapy.

To learn more about this program, the patient eligibility criteria, and to download the test requisition form, please visit our website.